Cogent Biosciences, Inc.
COGTNasdaq
$39.08
↑ +3.0%Jul 17 close · end-of-day
Price
1Y↑ +229.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.3B
Enterprise Value
$5.7B
P/E
—
P/S
—
P/B
10.4
EV/EBITDA
—
PEG
—
FCF Yield
-4.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$354.3M
Free Cash Flow (TTM)
-$286.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-58.3%
ROIC
—
Debt / Equity
0.4
Net Cash
$643.2M
Return 1Y
+220.3%
Company profile
Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.
- CEO
- Andrew R. Robbins
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Massachusetts
- Website
- cogentbio.com
Management & directors
- Robbins Andrews RPresident and CEO
- Green John L.Chief Financial Officer
- Kearns EvanChief Legal Officer
- Robinson John EdwardChief Scientific Officer
- Sachs JessicaChief Medical Officer
- Pinnow ColeChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
COGT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.53↑ +1.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.9M | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$82.2M | -$75.6M | -$147.8M | -$208.1M | -$275.9M | -$333.4M |
| Net income | -$74.8M | -$72.3M | -$140.2M | -$192.4M | -$255.9M | -$328.9M |
| Diluted EPS | — | -$1.87 | -$1.73 | -$1.94 | -$1.94 | -$2.16 |
| Operating cash flow | -$35.9M | -$58.8M | -$118.6M | -$153.6M | -$207.8M | -$264.4M |
| Free cash flow | — | -$60.5M | -$125.5M | -$156.4M | -$208.4M | -$266.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1044.3% | — | — | — | — | — |
| Net margin | -950.4% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$64.4M | -$75.4M | -$73.7M | -$74.9M | -$75.6M | -$83.4M | -$99.5M | -$103.6M |
| Net income | -$59.0M | -$70.6M | -$67.9M | -$72.0M | -$73.5M | -$80.9M | -$102.5M | -$97.4M |
| Diluted EPS | -$0.43 | -$0.52 | -$0.50 | -$0.52 | -$0.53 | -$0.50 | -$0.61 | -$0.53 |
| Operating cash flow | -$42.7M | -$52.0M | -$60.6M | -$66.5M | -$54.5M | -$64.3M | -$79.1M | -$86.9M |
| Free cash flow | -$42.8M | -$52.3M | -$60.7M | -$67.1M | -$54.7M | -$64.4M | -$79.9M | -$87.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jun 12, 2026
- 38d agoCogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trialfinance.yahoo.com
- 38d agoCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congressfinance.yahoo.com
- 38d agoCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congressfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-19 | Robbins Andrews R· President and CEO | Gift | 160,000 | $0.00 | $0.00 | filing |
| 2026-05-19 | Robbins Andrews R· President and CEO | Gift | 160,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Fairmount Funds Management LLC | Sale | 7,000,000 | $34.66 | $242.6M | filing |
| 2026-03-31 | Fairmount Funds Management LLC | C | 7,000,000 | — | — | filing |
| 2026-01-22 | Fairmount Funds Management LLC | Sale | 3,500,000 | $36.40 | $127.4M | filing |
| 2025-12-26 | Robinson John Edward· Chief Scientific Officer | Sale | 90,000 | $38.74 | $3.5M | filing |
| 2025-12-26 | Sachs Jessica· Chief Medical Officer | Sale | 82,642 | $38.70 | $3.2M | filing |
| 2025-12-26 | Green John L.· Chief Financial Officer | Sale | 77,000 | $38.68 | $3.0M | filing |
| 2025-12-26 | Kearns Evan· Chief Legal Officer | Sale | 65,000 | $38.70 | $2.5M | filing |
| 2025-12-17 | Robbins Andrews R· President and CEO | Tax withholding | 367,497 | $39.45 | $14.5M | filing |
| 2025-12-17 | Sachs Jessica· Chief Medical Officer | Tax withholding | 154,716 | $39.45 | $6.1M | filing |
| 2025-12-17 | Green John L.· Chief Financial Officer | Tax withholding | 145,007 | $39.45 | $5.7M | filing |
| 2025-12-17 | Robinson John Edward· Chief Scientific Officer | Tax withholding | 139,998 | $39.45 | $5.5M | filing |
| 2025-12-17 | Kearns Evan· Chief Legal Officer | Tax withholding | 125,602 | $39.45 | $5.0M | filing |
| 2025-12-17 | Pinnow Cole· Chief Commercial Officer | Tax withholding | 94,800 | $39.45 | $3.7M | filing |
| 2025-12-17 | Pinnow Cole· Chief Commercial Officer | Award | 214,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Kearns Evan· Chief Legal Officer | Award | 40,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Kearns Evan· Chief Legal Officer | Award | 260,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Sachs Jessica· Chief Medical Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Sachs Jessica· Chief Medical Officer | Award | 320,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Robinson John Edward· Chief Scientific Officer | Award | 320,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Green John L.· Chief Financial Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Green John L.· Chief Financial Officer | Award | 300,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Robbins Andrews R· President and CEO | Award | 185,000 | $0.00 | $0.00 | filing |
| 2025-12-17 | Robinson John Edward· Chief Scientific Officer | Award | 50,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.